{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.29","value":"65.8"},{"groupId":"OG001","spread":"31.55","value":"69.4"},{"groupId":"OG002","spread":"14.16","value":"58.3"},{"groupId":"OG003","spread":"13.18","value":"60.4"},{"groupId":"OG004","spread":"23.33","value":"56.2"},{"groupId":"OG005","spread":"9.72","value":"67.6"},{"groupId":"OG006","spread":"20.84","value":"63.6"},{"groupId":"OG007","spread":"20.78","value":"56.1"},{"groupId":"OG008","spread":"26.61","value":"60.2"},{"groupId":"OG009","spread":"24.60","value":"55.0"},{"groupId":"OG010","spread":"16.29","value":"63.3"},{"groupId":"OG011","spread":"15.71","value":"67.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"GHS/QoL, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.05","value":"-50.0"},{"groupId":"OG001","spread":"17.68","value":"4.2"},{"groupId":"OG002","spread":"14.43","value":"-4.2"},{"groupId":"OG003","spread":"18.00","value":"-16.7"},{"groupId":"OG004","spread":"34.05","value":"-10.0"},{"groupId":"OG005","spread":"11.79","value":"-8.3"},{"groupId":"OG006","spread":"13.94","value":"0.0"},{"groupId":"OG007","spread":"25.88","value":"-14.6"},{"groupId":"OG008","spread":"17.68","value":"-4.2"},{"groupId":"OG009","spread":"9.62","value":"-8.3"},{"groupId":"OG010","spread":"23.94","value":"18.7"},{"groupId":"OG011","spread":"20.97","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"GHS/QoL, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.82","value":"67.3"},{"groupId":"OG001","spread":"13.88","value":"88.9"},{"groupId":"OG002","spread":"15.65","value":"78.7"},{"groupId":"OG003","spread":"21.97","value":"73.3"},{"groupId":"OG004","spread":"15.60","value":"75.0"},{"groupId":"OG005","spread":"17.95","value":"84.4"},{"groupId":"OG006","spread":"17.34","value":"85.5"},{"groupId":"OG007","spread":"25.69","value":"70.9"},{"groupId":"OG008","spread":"31.27","value":"66.7"},{"groupId":"OG009","spread":"19.58","value":"78.7"},{"groupId":"OG010","spread":"10.91","value":"82.0"},{"groupId":"OG011","spread":"11.48","value":"89.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"PF, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.23","value":"-17.8"},{"groupId":"OG001","spread":"18.86","value":"13.3"},{"groupId":"OG002","spread":"24.94","value":"-6.7"},{"groupId":"OG003","spread":"33.11","value":"0.0"},{"groupId":"OG004","spread":"22.80","value":"-5.3"},{"groupId":"OG005","spread":"14.14","value":"-10.0"},{"groupId":"OG006","spread":"9.81","value":"-1.1"},{"groupId":"OG007","spread":"27.93","value":"-12.5"},{"groupId":"OG008","spread":"4.71","value":"3.3"},{"groupId":"OG009","spread":"15.87","value":"-10.0"},{"groupId":"OG010","spread":"42.64","value":"-11.7"},{"groupId":"OG011","spread":"12.62","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"PF, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.43","value":"66.7"},{"groupId":"OG001","spread":"19.25","value":"88.9"},{"groupId":"OG002","spread":"22.50","value":"76.7"},{"groupId":"OG003","spread":"29.46","value":"72.9"},{"groupId":"OG004","spread":"21.86","value":"68.1"},{"groupId":"OG005","spread":"22.05","value":"72.2"},{"groupId":"OG006","spread":"24.10","value":"81.8"},{"groupId":"OG007","spread":"36.03","value":"57.6"},{"groupId":"OG008","spread":"33.10","value":"70.4"},{"groupId":"OG009","spread":"19.56","value":"73.3"},{"groupId":"OG010","spread":"22.29","value":"71.7"},{"groupId":"OG011","spread":"19.80","value":"89.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"RF, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.39","value":"-22.2"},{"groupId":"OG001","spread":"23.57","value":"16.7"},{"groupId":"OG002","spread":"34.69","value":"8.3"},{"groupId":"OG003","spread":"34.36","value":"4.2"},{"groupId":"OG004","spread":"25.28","value":"-6.7"},{"groupId":"OG005","spread":"35.36","value":"-8.3"},{"groupId":"OG006","spread":"27.22","value":"-11.1"},{"groupId":"OG007","spread":"32.12","value":"0.0"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"34.36","value":"-20.8"},{"groupId":"OG010","spread":"36.96","value":"20.8"},{"groupId":"OG011","spread":"28.46","value":"-4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"RF, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.40","value":"76.7"},{"groupId":"OG001","spread":"4.81","value":"86.1"},{"groupId":"OG002","spread":"18.02","value":"77.5"},{"groupId":"OG003","spread":"16.93","value":"76.0"},{"groupId":"OG004","spread":"20.87","value":"70.8"},{"groupId":"OG005","spread":"7.22","value":"94.4"},{"groupId":"OG006","spread":"25.50","value":"73.5"},{"groupId":"OG007","spread":"28.89","value":"68.9"},{"groupId":"OG008","spread":"13.18","value":"83.3"},{"groupId":"OG009","spread":"17.21","value":"78.3"},{"groupId":"OG010","spread":"16.20","value":"83.3"},{"groupId":"OG011","spread":"8.91","value":"91.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"EF, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.27","value":"5.6"},{"groupId":"OG001","spread":"5.89","value":"-12.5"},{"groupId":"OG002","spread":"0.00","value":"0.0"},{"groupId":"OG003","spread":"15.77","value":"10.4"},{"groupId":"OG004","spread":"33.64","value":"3.3"},{"groupId":"OG005","spread":"23.57","value":"-16.7"},{"groupId":"OG006","spread":"11.79","value":"0.0"},{"groupId":"OG007","spread":"25.49","value":"-6.3"},{"groupId":"OG008","spread":"5.89","value":"-12.5"},{"groupId":"OG009","spread":"14.23","value":"2.1"},{"groupId":"OG010","spread":"15.96","value":"-12.5"},{"groupId":"OG011","spread":"12.50","value":"6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"EF, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.20","value":"75.0"},{"groupId":"OG001","spread":"9.62","value":"88.9"},{"groupId":"OG002","spread":"24.91","value":"71.7"},{"groupId":"OG003","spread":"21.71","value":"72.9"},{"groupId":"OG004","spread":"19.41","value":"81.9"},{"groupId":"OG005","spread":"13.89","value":"87.0"},{"groupId":"OG006","spread":"17.41","value":"81.8"},{"groupId":"OG007","spread":"15.57","value":"74.2"},{"groupId":"OG008","spread":"16.90","value":"74.1"},{"groupId":"OG009","spread":"22.22","value":"83.3"},{"groupId":"OG010","spread":"8.05","value":"95.0"},{"groupId":"OG011","spread":"12.60","value":"91.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"CF, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.10","value":"-16.7"},{"groupId":"OG001","spread":"11.79","value":"8.3"},{"groupId":"OG002","spread":"19.25","value":"16.7"},{"groupId":"OG003","spread":"20.97","value":"12.5"},{"groupId":"OG004","spread":"25.28","value":"-10.0"},{"groupId":"OG005","spread":"23.57","value":"-16.7"},{"groupId":"OG006","spread":"6.80","value":"2.8"},{"groupId":"OG007","spread":"17.82","value":"0.0"},{"groupId":"OG008","spread":"11.79","value":"8.3"},{"groupId":"OG009","spread":"21.52","value":"-8.3"},{"groupId":"OG010","spread":"27.22","value":"-16.7"},{"groupId":"OG011","spread":"9.62","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"CF, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.12","value":"71.7"},{"groupId":"OG001","spread":"19.25","value":"88.9"},{"groupId":"OG002","spread":"18.92","value":"80.0"},{"groupId":"OG003","spread":"21.71","value":"77.1"},{"groupId":"OG004","spread":"20.67","value":"76.4"},{"groupId":"OG005","spread":"18.63","value":"83.3"},{"groupId":"OG006","spread":"28.16","value":"77.3"},{"groupId":"OG007","spread":"28.95","value":"71.2"},{"groupId":"OG008","spread":"34.36","value":"72.2"},{"groupId":"OG009","spread":"34.65","value":"68.3"},{"groupId":"OG010","spread":"17.92","value":"73.3"},{"groupId":"OG011","spread":"23.57","value":"75.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"SF, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.10","value":"-27.8"},{"groupId":"OG001","spread":"11.79","value":"8.3"},{"groupId":"OG002","spread":"23.57","value":"0.0"},{"groupId":"OG003","spread":"36.96","value":"-12.5"},{"groupId":"OG004","spread":"25.28","value":"-6.7"},{"groupId":"OG005","spread":"0.00","value":"-16.7"},{"groupId":"OG006","spread":"22.77","value":"-11.1"},{"groupId":"OG007","spread":"36.66","value":"-27.1"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"16.67","value":"8.3"},{"groupId":"OG010","spread":"34.36","value":"-12.5"},{"groupId":"OG011","spread":"19.25","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"SF, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.89","value":"46.7"},{"groupId":"OG001","spread":"16.97","value":"25.9"},{"groupId":"OG002","spread":"8.76","value":"31.1"},{"groupId":"OG003","spread":"19.70","value":"38.9"},{"groupId":"OG004","spread":"19.22","value":"34.3"},{"groupId":"OG005","spread":"21.60","value":"28.4"},{"groupId":"OG006","spread":"13.40","value":"29.3"},{"groupId":"OG007","spread":"26.51","value":"34.3"},{"groupId":"OG008","spread":"30.32","value":"30.9"},{"groupId":"OG009","spread":"23.10","value":"32.2"},{"groupId":"OG010","spread":"25.77","value":"37.8"},{"groupId":"OG011","spread":"3.93","value":"31.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Fatigue, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.72","value":"3.7"},{"groupId":"OG001","spread":"15.71","value":"-11.1"},{"groupId":"OG002","spread":"6.42","value":"5.6"},{"groupId":"OG003","spread":"24.64","value":"2.8"},{"groupId":"OG004","spread":"28.76","value":"13.3"},{"groupId":"OG005","spread":"15.71","value":"-11.1"},{"groupId":"OG006","spread":"13.46","value":"-3.7"},{"groupId":"OG007","spread":"33.60","value":"16.7"},{"groupId":"OG008","spread":"15.71","value":"11.1"},{"groupId":"OG009","spread":"18.98","value":"2.8"},{"groupId":"OG010","spread":"41.94","value":"-2.8"},{"groupId":"OG011","spread":"12.83","value":"-11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Fatigue, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.81","value":"11.7"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"15.81","value":"11.7"},{"groupId":"OG003","spread":"5.89","value":"2.1"},{"groupId":"OG004","spread":"15.08","value":"8.3"},{"groupId":"OG005","spread":"7.35","value":"3.7"},{"groupId":"OG006","spread":"7.78","value":"4.5"},{"groupId":"OG007","spread":"5.03","value":"1.5"},{"groupId":"OG008","spread":"8.33","value":"5.6"},{"groupId":"OG009","spread":"11.79","value":"8.3"},{"groupId":"OG010","spread":"8.05","value":"5.0"},{"groupId":"OG011","spread":"5.89","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"N/V, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.94","value":"11.1"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"8.33","value":"4.2"},{"groupId":"OG003","spread":"8.33","value":"-4.2"},{"groupId":"OG004","spread":"30.28","value":"-6.7"},{"groupId":"OG005","spread":"11.79","value":"-8.3"},{"groupId":"OG006","spread":"17.21","value":"5.6"},{"groupId":"OG007","spread":"12.40","value":"6.3"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"8.33","value":"-4.2"},{"groupId":"OG010","spread":"8.33","value":"4.2"},{"groupId":"OG011","spread":"13.61","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"N/V, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.83","value":"46.7"},{"groupId":"OG001","spread":"25.46","value":"22.2"},{"groupId":"OG002","spread":"24.60","value":"36.7"},{"groupId":"OG003","spread":"31.81","value":"37.5"},{"groupId":"OG004","spread":"26.11","value":"41.7"},{"groupId":"OG005","spread":"29.00","value":"24.1"},{"groupId":"OG006","spread":"25.92","value":"28.8"},{"groupId":"OG007","spread":"34.52","value":"34.8"},{"groupId":"OG008","spread":"33.45","value":"42.6"},{"groupId":"OG009","spread":"20.86","value":"28.3"},{"groupId":"OG010","spread":"25.82","value":"36.7"},{"groupId":"OG011","spread":"21.71","value":"22.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Pain, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"0.0"},{"groupId":"OG001","spread":"47.14","value":"-16.7"},{"groupId":"OG002","spread":"15.96","value":"-12.5"},{"groupId":"OG003","spread":"50.00","value":"-25.0"},{"groupId":"OG004","spread":"36.13","value":"20.0"},{"groupId":"OG005","spread":"23.57","value":"-16.7"},{"groupId":"OG006","spread":"8.61","value":"-5.6"},{"groupId":"OG007","spread":"30.54","value":"12.5"},{"groupId":"OG008","spread":"11.79","value":"-8.3"},{"groupId":"OG009","spread":"31.91","value":"25.0"},{"groupId":"OG010","spread":"43.83","value":"-4.2"},{"groupId":"OG011","spread":"16.67","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Pain, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.14","value":"33.3"},{"groupId":"OG001","spread":"19.25","value":"11.1"},{"groupId":"OG002","spread":"17.21","value":"13.3"},{"groupId":"OG003","spread":"17.25","value":"12.5"},{"groupId":"OG004","spread":"25.95","value":"22.2"},{"groupId":"OG005","spread":"16.67","value":"11.1"},{"groupId":"OG006","spread":"17.41","value":"15.2"},{"groupId":"OG007","spread":"36.51","value":"33.3"},{"groupId":"OG008","spread":"24.22","value":"14.8"},{"groupId":"OG009","spread":"17.57","value":"16.7"},{"groupId":"OG010","spread":"17.57","value":"16.7"},{"groupId":"OG011","spread":"15.43","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Dyspnoea, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.33","value":"33.3"},{"groupId":"OG001","spread":"23.57","value":"-16.7"},{"groupId":"OG002","spread":"31.91","value":"25.0"},{"groupId":"OG003","spread":"19.25","value":"16.7"},{"groupId":"OG004","spread":"23.57","value":"0.0"},{"groupId":"OG005","spread":"0.00","value":"0.0"},{"groupId":"OG006","spread":"13.61","value":"-5.6"},{"groupId":"OG007","spread":"39.59","value":"12.5"},{"groupId":"OG008","spread":"23.57","value":"16.7"},{"groupId":"OG009","spread":"0.00","value":"0.0"},{"groupId":"OG010","spread":"19.25","value":"16.7"},{"groupId":"OG011","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Dyspnoea, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.29","value":"40.0"},{"groupId":"OG001","spread":"38.49","value":"44.4"},{"groupId":"OG002","spread":"27.22","value":"33.3"},{"groupId":"OG003","spread":"21.36","value":"29.2"},{"groupId":"OG004","spread":"33.21","value":"36.1"},{"groupId":"OG005","spread":"14.70","value":"25.9"},{"groupId":"OG006","spread":"25.03","value":"27.3"},{"groupId":"OG007","spread":"33.33","value":"33.3"},{"groupId":"OG008","spread":"38.89","value":"37.0"},{"groupId":"OG009","spread":"31.43","value":"33.3"},{"groupId":"OG010","spread":"33.15","value":"30.0"},{"groupId":"OG011","spread":"15.43","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Insomnia, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.33","value":"0.0"},{"groupId":"OG001","spread":"47.14","value":"0.0"},{"groupId":"OG002","spread":"19.25","value":"-16.7"},{"groupId":"OG003","spread":"27.22","value":"0.0"},{"groupId":"OG004","spread":"27.89","value":"-6.7"},{"groupId":"OG005","spread":"23.57","value":"-16.7"},{"groupId":"OG006","spread":"25.09","value":"5.6"},{"groupId":"OG007","spread":"23.57","value":"8.3"},{"groupId":"OG008","spread":"47.14","value":"0.0"},{"groupId":"OG009","spread":"19.25","value":"-16.7"},{"groupId":"OG010","spread":"54.43","value":"0.0"},{"groupId":"OG011","spread":"0.00","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Insomnia, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.44","value":"23.3"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"14.05","value":"6.7"},{"groupId":"OG003","spread":"23.57","value":"25.0"},{"groupId":"OG004","spread":"22.29","value":"13.9"},{"groupId":"OG005","spread":"14.70","value":"7.4"},{"groupId":"OG006","spread":"16.82","value":"12.1"},{"groupId":"OG007","spread":"15.57","value":"9.1"},{"groupId":"OG008","spread":"23.57","value":"22.2"},{"groupId":"OG009","spread":"26.29","value":"26.7"},{"groupId":"OG010","spread":"14.05","value":"6.7"},{"groupId":"OG011","spread":"24.80","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"AL, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.25","value":"22.2"},{"groupId":"OG001","spread":"23.57","value":"16.7"},{"groupId":"OG002","spread":"19.25","value":"16.7"},{"groupId":"OG003","spread":"19.25","value":"-16.7"},{"groupId":"OG004","spread":"33.33","value":"0.0"},{"groupId":"OG005","spread":"23.57","value":"16.7"},{"groupId":"OG006","spread":"0.00","value":"0.0"},{"groupId":"OG007","spread":"21.36","value":"-4.2"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"41.94","value":"-8.3"},{"groupId":"OG010","spread":"50.00","value":"25.0"},{"groupId":"OG011","spread":"16.67","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"AL, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.11","value":"20.0"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"14.05","value":"6.7"},{"groupId":"OG003","spread":"17.25","value":"12.5"},{"groupId":"OG004","spread":"26.59","value":"16.7"},{"groupId":"OG005","spread":"16.67","value":"11.1"},{"groupId":"OG006","spread":"16.82","value":"12.1"},{"groupId":"OG007","spread":"15.57","value":"9.1"},{"groupId":"OG008","spread":"22.22","value":"7.4"},{"groupId":"OG009","spread":"17.21","value":"13.3"},{"groupId":"OG010","spread":"32.20","value":"20.0"},{"groupId":"OG011","spread":"15.43","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Constipation, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"0.0"},{"groupId":"OG001","spread":"23.57","value":"16.7"},{"groupId":"OG002","spread":"33.33","value":"16.7"},{"groupId":"OG003","spread":"33.33","value":"16.7"},{"groupId":"OG004","spread":"0.00","value":"0.0"},{"groupId":"OG005","spread":"47.14","value":"0.0"},{"groupId":"OG006","spread":"0.00","value":"0.0"},{"groupId":"OG007","spread":"21.36","value":"4.2"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"0.00","value":"0.0"},{"groupId":"OG010","spread":"31.91","value":"-25.0"},{"groupId":"OG011","spread":"19.25","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Constipation, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.05","value":"6.7"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"23.57","value":"16.7"},{"groupId":"OG003","spread":"15.43","value":"8.3"},{"groupId":"OG004","spread":"22.29","value":"19.4"},{"groupId":"OG005","spread":"16.67","value":"11.1"},{"groupId":"OG006","spread":"15.57","value":"9.1"},{"groupId":"OG007","spread":"34.23","value":"21.2"},{"groupId":"OG008","spread":"33.33","value":"11.1"},{"groupId":"OG009","spread":"21.08","value":"6.7"},{"groupId":"OG010","spread":"14.05","value":"6.7"},{"groupId":"OG011","spread":"17.25","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"Diarrhoea, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.25","value":"22.2"},{"groupId":"OG001","spread":"47.14","value":"33.3"},{"groupId":"OG002","spread":"31.91","value":"8.3"},{"groupId":"OG003","spread":"16.67","value":"8.3"},{"groupId":"OG004","spread":"29.81","value":"-13.3"},{"groupId":"OG005","spread":"23.57","value":"-16.7"},{"groupId":"OG006","spread":"13.61","value":"-5.6"},{"groupId":"OG007","spread":"30.86","value":"0.0"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"27.22","value":"0.0"},{"groupId":"OG010","spread":"19.25","value":"16.7"},{"groupId":"OG011","spread":"31.91","value":"-8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"Diarrhoea, CFB to EoT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.15","value":"30.0"},{"groupId":"OG001","spread":"19.25","value":"11.1"},{"groupId":"OG002","spread":"36.68","value":"30.0"},{"groupId":"OG003","spread":"0.00","value":"0.0"},{"groupId":"OG004","spread":"30.01","value":"36.1"},{"groupId":"OG005","spread":"14.70","value":"7.4"},{"groupId":"OG006","spread":"36.79","value":"24.2"},{"groupId":"OG007","spread":"17.41","value":"15.2"},{"groupId":"OG008","spread":"27.78","value":"25.9"},{"groupId":"OG009","spread":"37.84","value":"26.7"},{"groupId":"OG010","spread":"35.83","value":"20.0"},{"groupId":"OG011","spread":"35.36","value":"20.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"title":"FD, Baseline (Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.74","value":"33.3"},{"groupId":"OG001","spread":"0.00","value":"0.0"},{"groupId":"OG002","spread":"31.91","value":"8.3"},{"groupId":"OG003","spread":"0.00","value":"0.0"},{"groupId":"OG004","spread":"18.26","value":"-13.3"},{"groupId":"OG005","spread":"0.00","value":"0.0"},{"groupId":"OG006","spread":"0.00","value":"0.0"},{"groupId":"OG007","spread":"21.36","value":"4.2"},{"groupId":"OG008","spread":"0.00","value":"0.0"},{"groupId":"OG009","spread":"19.25","value":"16.7"},{"groupId":"OG010","spread":"16.67","value":"8.3"},{"groupId":"OG011","spread":"33.33","value":"-16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"title":"FD, CFB to EoT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"8"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \\[PF\\], role functioning \\[RF\\], cognitive functioning \\[CF\\], emotional functioning \\[EF\\] and social functioning \\[SF\\]), three symptom scales (fatigue, pain and nausea/vomiting \\[N/V\\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss \\[AL\\] and financial difficulties \\[FD\\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose visit value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 1.9 milligram (mg)/kilogram (kg) dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide (Len) was administered as 25 mg or 10 mg per oral (PO) on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone (Dex) weekly PO/ intravenously (IV) on Days 1, 8, 15 and 22 of each cycle.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg STRETCH + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SPLIT + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 28-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Lenalidomide was administered as 25 mg or 10 mg PO on Days 1-21 of each 28-day cycle with 40 mg Dexamethasone weekly PO/ IV on Days 1, 8, 15 and 22 of each cycle.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5mg/kg SINGLE + Len/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG008","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG009","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG010","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG011","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEAN","populationDescription":"All Treated. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 4.5 years (End of treatment [EoT])","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score","type":"SECONDARY","unitOfMeasure":"Score on scale"}